research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
== Adverse effects == Preclinical, phase I, and phase II clinical trials indicated that tirzepatide exhibits adverse effects similar to those of other established GLP-1 receptor agonists, such as dulaglutide (sold as Trulicity) and semaglutide (sold as Wegovy, Ozempic, and Rybelsus). These effects occur largely in the gastrointestinal tract. In the phase-II randomized controlled trial of tirzepatide for type II diabetes published in The Lancet in 2018, the most frequently observed symptoms were nausea, diarrhea, and vomiting, which increase in incidence as dosage increases. The proportion of patients who discontinued taking tirzepatide also increased as the dosage increased, with patients taking 15 mg having a 25% discontinuation rate and 5.1% of those taking 5 mg. To a slightly lesser extent, patients also reported reduced appetite. Other side effects reported were dyspepsia, constipation, abdominal pain, dizziness, and hypoglycemia. A systematic review published in 2024 found that tirzepatide was well tolerated and not associated with pancreatitis, but later case reports have found that pancreatitis sometimes follows initiation of treatment with tirzepatide. In 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance on GLP-1 medications after an increase in reports to the agency's Yellow Card Scheme of acute pancreatitis, with fatalities, in patients taking semaglutide or tirzepatide, to warn of a small risk of developing severe acute pancreatitis.
Mitragynine is an indole-based alkaloid and is one of the main psychoactive constituents in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. It has also been researched for its use to potentially manage symptoms of opioid withdrawal. It is a partial agonist of the μ-opioid receptors; and as such can produce effects similar to those of classic opioids such as morphine. Mitragynine is the most abundant active alkaloid in kratom. In Thai varieties of kratom, mitragynine is the most abundant component (up to 66% of total alkaloids), while 7-hydroxymitragynine (7-OH-MIT) is a minor constituent (up to 2% of total alkaloid content). In Malaysian kratom varieties, mitragynine is present at lower concentration (12% of total alkaloids). Total alkaloid concentration in dried leaves ranges from 0.5–1.5%. Such preparations are orally consumed and typically involve dried kratom leaves which are brewed into tea or ground and placed into capsules.
=== Ethiopia === Ethiopia is experiencing a severe fuel crisis, with over 180,000 tonnes of fuel undelivered in recent weeks. This has halved the country's daily diesel supply from 9.2 million to 4.5 million litres, according to Minister Kassahun Gofe. In Ethiopia, security institutions have been prioritised, along with, major government projects, key industries, and essential goods production. There are fuel restrictions, and petrol stations are prioritising public transport. Fuel supplies to the Tigray Region have been completely suspended. Addis Ababa residents have reported that, “Over the past month, prices of many commodities have increased significantly ...bottled water, cooking oil, eggs and other essentials have risen by nearly 40 per cent.”
moderate to severe, diffuse abdominal pain constipation abdominal distension nausea/vomiting, especially after meals vomiting of bilious fluid (green or yellowish-green in colour) flatulence or inability to pass gas excessive belching
=== Connection with Cancer treatment === hCTR1 is upregulated in various cancer types, and it's associated with prognosis in several solid tumors. Atox1 and ATP7B were found to be important for Pt-based drug resistance. hCTR1 plays a role in oncology, hCTR1 facilitates uptake of platinum-based chemotherapeutic agents, such as cisplatin. Yeast and mammalian cells lacking CTR1 were resistant to cisplatin, while cells overexpressing CTR1 accumulated more of the drug. Tumor cells when exposed to cisplatin often react by increased degradation of hCTR1, thereby they become drug-resistant while simultaneously exhibiting signs of perturbed copper homeostasis. Studies of Atox1 in cancer cells demonstrated that this copper chaperone is crucial for cancer cell proliferation and survival. Small molecules targeting Atox1 have been proved to effectively block Cu-trafficking. For that reason reduce cell proliferation in lung, leukemia, breast, head, and neck cancer cell lines by elevating cellular ROS levels and reducing cellular NADPH and GSH levels. In contrast, healthy cells were barely affected by these small molecules.
Sources: en.wikipedia.org
=== Second World War === The Special Air Service was a unit of the British Army during the Second World War that was formed in July 1941 by David Stirling and originally called "L" Detachment, Special Air Service Brigade – the "L" designation and Air Service name being a tie-in to a British disinformation campaign, trying to deceive the Axis into thinking there was a paratrooper regiment with numerous units operating in the area (the real SAS would "prove" to the Axis that the fake one existed). It was conceived as a commando force to operate behind enemy lines in the North African Campaign and initially consisted of five officers and 60 other ranks. Its first mission, in November 1941, was a parachute drop in support of the Operation Crusader offensive, codenamed Operation Squatter. Due to German resistance and adverse weather conditions, the mission was a disaster, with only 22 men, a third of the unit, making it back to base. The rest were either killed or captured. Its second mission was a major success. Transported by the Long Range Desert Group, it attacked three airfields in Libya, destroying 60 aircraft without loss. In September 1942, it was renamed 1st SAS, consisting at that time of four British squadrons, one Free French, one Greek, and the Folboat Section.
An analysis of GPX1 expression in oligodendrocytes from patients with major depressive disorder and control patients showed that GPX1 levels were significantly decreased in patients with the disorder, but not in their astrocytes. Shortening of telomeres and decreased expression of telomerase were also evident in these oligodendrocytes, but not in the astrocytes in these patients. This suggests that decreased oxidative stress protection, as observed by decreased GPX1 levels, and decreased telomerase expression may help give rise to telomere shortening in patients with MDD.
=== Mites and insects === Ivermectin is also used to treat infection with parasitic arthropods. Scabies – infestation with the mite Sarcoptes scabiei – is most commonly treated with topical permethrin or oral ivermectin. A single application of permethrin is more efficacious than a single treatment of ivermectin. For most scabies cases, ivermectin is used in a two-dose regimen: the first dose kills the active mites, but not their eggs. Over the next week, the eggs hatch, and a second dose kills the newly hatched mites. The two-dose regimen of ivermectin has similar efficacy to the single dose permethrin treatment. Ivermectin is, however, more effective than permethrin when used in the mass treatment of endemic scabies. Similarly, oral ivermectin is increasingly used to control scabies outbreaks in semi-closed institutions (care homes, refugee camps, prisons etc.), where mass topical treatments often fail for logistical reasons. For severe "crusted scabies", where the parasite burden is orders of magnitude higher than usual, the CDC recommends up to seven doses of ivermectin over the course of a month, along with a topical antiparasitic. Both head lice and pubic lice can be treated with oral ivermectin, an ivermectin lotion applied directly to the affected area, or various other insecticides. Ivermectin is also used to treat rosacea and blepharitis, both of which can be caused or exacerbated by Demodex folliculorum mites.
Chain Home, or CH for short, was the codename for the ring of coastal early warning radar stations built by the Royal Air Force (RAF) before and during the Second World War to detect and track aircraft. Initially known as RDF, and given the official name Air Ministry Experimental Station Type 1 (AMES Type 1) in 1940, the radar units were also known as Chain Home for most of their life. Chain Home was the first early warning radar network in the world and the first military radar system to reach operational status. Its effect on the war made it one of the most powerful systems of what became known as the "Wizard War". In late 1934, the Tizard Committee asked radio expert Robert Watson-Watt to comment on the repeated claims of radio death rays and reports suggesting Germany had built some sort of radio weapon. His assistant, Arnold Wilkins, demonstrated that a death ray was impossible but suggested radio could be used for long-range detection. In February 1935, a successful demonstration was arranged by placing a receiver near a BBC short wave transmitter and flying an aircraft around the area. Using commercial short wave radio hardware, Watt's team built a prototype pulsed transmitter and, by June 1935, it detected an aircraft that happened to be flying past. Basic development was completed by the end of the year, with detection ranges on the order of 100 mi (160 km). In 1936, attention was focused on a production version, and early 1937 saw the addition of height finding.
Sources: en.wikipedia.org
===== MeSH D08.811.682.664 – oxidoreductases acting on ch-nh2 group donors ===== MeSH D08.811.682.664.249 – amine oxidase (copper-containing) MeSH D08.811.682.664.500 – amino acid oxidoreductases MeSH D08.811.682.664.500.062 – alanine dehydrogenase MeSH D08.811.682.664.500.125 – d-amino-acid oxidase MeSH D08.811.682.664.500.261 – d-aspartate oxidase MeSH D08.811.682.664.500.398 – glutamate dehydrogenase MeSH D08.811.682.664.500.410 – glutamate dehydrogenase (nadp+) MeSH D08.811.682.664.500.470 – glutamate synthase (NADPH) MeSH D08.811.682.664.500.484 – glutamate synthase (NADH) MeSH D08.811.682.664.500.498 – glycine decarboxylase complex MeSH D08.811.682.664.500.498.500 – glycine dehydrogenase (decarboxylating) MeSH D08.811.682.664.500.526 – glycine dehydrogenase MeSH D08.811.682.664.500.677 – l-amino acid oxidase MeSH D08.811.682.664.500.724 – leucine dehydrogenase MeSH D08.811.682.664.500.772 – nitric oxide synthase MeSH D08.811.682.664.500.772.249 – nitric oxide synthase type i MeSH D08.811.682.664.500.772.500 – nitric oxide synthase type ii MeSH D08.811.682.664.500.772.750 – nitric oxide synthase type iii MeSH D08.811.682.664.500.810 – proline oxidase MeSH D08.811.682.664.500.848 – protein-lysine 6-oxidase MeSH D08.811.682.664.500.924 – valine dehydrogenase (NADP+) MeSH D08.811.682.664.750 – monoamine oxidase MeSH D08.811.682.664.750.100 – benzylamine oxidase
== Protein == Seryl-tRNA synthetase is made up of 514 amino acid residues as weighs 58,777 Da. It exists as a homodimer of two identical subunits, with the tRNA molecule binding across the dimer by similarity. It has two distinct domains:
Canada (1974) Australia (1981) Israel (1983) UK (1987) Netherlands (2010) In 2012, JDF changed its name to Juvenile Diabetes Research Foundation, which was later shortened to JDRF. In 2019, JDRF International appointed its first-ever CEO and president with type 1 diabetes, Dr. Aaron Kowalski. In 2024, the international chapters of the organization began to change their name from JDRF to Breakthrough T1D, reflecting its focus on helping people of all ages and in line with growing awareness that T1D affects people of all ages. The Australian affiliate was the last to change their name on March 31, 2025.
=== Disbandment === Ahead of the multi-racial 1980 Southern Rhodesian general election the Selous Scouts and SAS were involved in preparing plans to annul its results. One of these plans would have involved killing the leadership of the black nationalist parties in Operation Hectic. Another, designated Operation Quartz would have involved attacking the insurgents in the camps where they had been concentrated within Rhodesia ahead of the election. These operations were not attempted. Following the transition to majority rule and Rhodesia's reconstitution as Zimbabwe, Prime Minister Robert Mugabe decided in March 1980 to disband the Selous Scouts by April that year. Mugabe stated that the unit needed to be disbanded as part of reforms to provide Zimbabwe with a "respectable" army. At this time it was expected that many of its white members would leave the military. Walls received a hostile reception from the unit's officers and men when he visited its base in March 1980. During this visit members of the Selous Scouts called him a traitor. The Selous Scouts were disbanded without a formal ceremony to mark the occasion in April 1980. The unit had suffered between 30 and 35 fatalities during its existence. Most of the white members of the Selous Scouts moved to South Africa to join that country's security forces. The 900 black members of the unit were offered other positions within Zimbabwe's security forces, and were mainly split across three battalions of the Rhodesian African Rifles.
On 3 December 1984, over 500,000 people in the vicinity of the Union Carbide India Limited pesticide plant in Bhopal, Madhya Pradesh, India, were exposed to the highly toxic gas methyl isocyanate, in what is considered the world's worst industrial disaster. A government affidavit in 2006 stated that the leak caused approximately 558,125 injuries, including 38,478 temporary partial injuries and 3,900 severely and permanently disabling injuries. Estimates vary on the death toll, with the official number of immediate deaths being 2,259. Others estimate that 8,000 died within two weeks of the incident occurring, and another 8,000 or more died from gas-related diseases. In 1989, Union Carbide Corporation (UCC) of the United States paid $470 million (equivalent to $1.03 billion in 2024) to settle litigation stemming from the disaster. The owner of the factory, Union Carbide India Limited (UCIL), was a publicly-traded company which was majority-owned and controlled by the UCC, while the remaining 49.1 percent stake was held by the Indian public and Indian government-controlled banks. In 1994, UCC sold its stake in UCIL to Eveready Industries India Limited (EIIL), which subsequently merged with McLeod Russel (India) Ltd. Eveready ended clean-up on the site in 1998, when it terminated its 99-year lease and turned over control of the site to the state government of Madhya Pradesh. Dow Chemical Company purchased UCC in 2001, seventeen years after the disaster.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.